Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

ClinicalTrials.gov ID: NCT01670877

Public ClinicalTrials.gov record NCT01670877. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.

Study identification

NCT ID: NCT01670877
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Washington University School of Medicine; Other
Enrollment: 56 participants

Conditions and interventions

Conditions

Breast Neoplasms

Interventions

Drug · Procedure

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 10, 2012
Primary completion: Feb 10, 2021
Completion: Mar 10, 2021
Last update posted: Apr 14, 2022

2012 – 2021

United States locations

U.S. sites: 15
U.S. states: 11
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of Alabama Cancer Center	Birmingham	Alabama	35294	—
Mayo Clinic	Phoenix	Arizona	85054	—
University of Southern California Keck School of Medicine	Los Angeles	California	90033	—
Stanford Medicine Cancer Institute	Stanford	California	94305	—
University of Miami Hospital and Clinics	Miami	Florida	33136	—
Northwestern University - Feinberg School of Medicine	Chicago	Illinois	60611	—
Rush University Medical Center	Chicago	Illinois	60612	—
Dana-Farber Cancer Institute, Harvard University	Boston	Massachusetts	02215	—
University of Michigan	Ann Arbor	Michigan	48109	—
St. Luke's Cancer Institute	Kansas City	Missouri	64111	—
Washington University School of Medicine	St Louis	Missouri	63110	—
University of North Carolina at Chapel Hill (Lineberger Comprehensive Cancer Center)	Chapel Hill	North Carolina	27514	—
Duke Cancer Institute at Duke University Medical Center	Durham	North Carolina	27710	—
Avera Cancer Institute	Sioux Falls	South Dakota	57105	—
Baylor College of Medicine	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01670877, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 14, 2022 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01670877 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →